Profile for Norway Patent: 20065417

US Patent Family Members and Approved Drugs for Norway Patent: 20065417

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Dec 18, 2027	Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate
	Dec 18, 2027	Glaxo Grp England	INCRUSE ELLIPTA	umeclidinium bromide
	Dec 18, 2027	Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate
	Apr 27, 2025	Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate
	Apr 27, 2025	Glaxo Grp England	INCRUSE ELLIPTA	umeclidinium bromide

Analysis of Patent NO20065417: Scope, Claims, and Landscape

Last updated: July 29, 2025

---

Introduction

Patent NO20065417 pertains to a chemical compound, formulation, or method associated with pharmaceutical applications, granted in Norway. Precise details such as inventors, assignees, and specific claims reveal the scope of exclusivity, innovation breadth, and strategic positioning within the global patent landscape. This analysis aims to elucidate the patent’s scope of protection, examine its claims, and contextualize its position within the pharmaceutical patent environment.

---

Patent Overview and Filing Context

Patent NO20065417, filed on or around 2006, emerges during a period when biotechnology and small-molecule drugs experienced significant innovation. The patent’s jurisdiction in Norway, a member of the European Patent Convention (EPC), allows for validation in multiple European countries, augmenting its scope.

The patent appears aligned with novel compounds or formulations intended for therapeutic use, possibly targeting prevalent medical conditions such as neurodegenerative diseases, cancers, or metabolic disorders (common themes in patents filed during that period). The patent holder's strategic intent often aims to carve out a robust